Alfonso Vargas has over 7 years of in-vitro diagnostic experience in and out of the laboratory and over 4 years of clinical and regulatory affairs experience. Alfonso’s extensive experience in IVD research and clinical trials ranges from early stage research & development to post-market clinical studies. Alfonso’s work has focused on infectious diseases and cardiac biomarkers. Alfonso has been a key member in obtaining FDA clearances at point-of care settings, 510K & CLIA waived approvals and Emergency Use Authorizations (EUA) for sexually transmitted infections, COVID-19, blood gases, and cardiac biomarkers.